[Effect of bezafibrate on lipid and apoprotein levels in patients with idiopathic hypertriglyceridemia].
D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000097:blood*; D001629:Bezafibrate; D002784:Cholesterol / Q000097:blood; D002994:Clofibrate / Q000031:analogs & derivatives*; D002995:Clofibric Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000097:blood / Q000188:drug therapy*; D006953:Hyperlipoproteinemia Type IV / Q000097:blood / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood*
D001053:Apolipoproteins; D000960:Hypolipidemic Agents; D014280:Triglycerides; D002995:Clofibric Acid; D002784:Cholesterol; D002994:Clofibrate; D001629:Bezafibrate
Ocena wpływu bezafibratu na poziom lipidów i apolipoprotein u pacjentów z hipertrójglicerydemiq samoistnq.